| (Values in U.S. Thousands) | May, 2026 | May, 2026 | May, 2026 | May, 2026 | May, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Correvio Pharma Corp (CORV.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial Fibrillation, Hospital Acquired Pneumonia & Community Acquired Pneumonia, Pulmonary Arterial Hypertension, and Supraventricular Tachycardia. The firm earns revenue from the sale of company's commercialized products. It has Europe and Rest of the world geographic segments.